CN109998151B

CN109998151B - Use of medium chain triglycerides for improving and/or reducing respiratory tract irritation

Info

Publication number: CN109998151B
Application number: CN201910293507.3A
Authority: CN
Inventors: 谭昕; 朱贝利; 金倩
Original assignee: Hanyi Bio Technology Beijing Co ltd
Current assignee: Hanyi Bio Technology Beijing Co ltd
Priority date: 2019-04-12
Filing date: 2019-04-12
Publication date: 2021-11-26
Anticipated expiration: 2039-04-12
Also published as: CN109998151A

Abstract

The present invention provides the use of medium chain triglycerides for ameliorating and/or reducing respiratory irritation, preferably caused by the administration of a tobacco product, preferably propylene glycol in a tobacco product.

Description

Use of medium chain triglycerides for improving and/or reducing respiratory tract irritation

Technical Field

The invention belongs to the field of tobacco products, and particularly relates to application of medium-chain triglyceride in improving and/or reducing the respiratory tract irritation of tobacco products, in particular to application of medium-chain triglyceride in improving and/or reducing the respiratory tract irritation caused by propylene glycol.

Background

With the improvement of living standard, the consumption of cigarette is increased rapidly, and the number of smokers reaches nearly 10 hundred million people all over the world according to the statistics of the World Health Organization (WHO). The smoke generated during smoking enters from the mouth, passes through throat, trachea and bronchus, enters into blood, has the biggest harm to respiratory tract due to smoking, is easy to cause cough diseases such as laryngitis, tracheitis, emphysema and the like, and also increases cancer risk, and in the preliminary reference of cancerogen list published by the WHO international cancer research institution in 2017, smoking is a kind of cancerogen.

As mentioned above, cigarette smoke mainly flows through the respiratory tract and is a major hazard to the respiratory system. Cilia, which are capable of vibrating, grow on the mucosa of the trachea and bronchi, protecting the airways and keeping it clean under normal conditions. Nicotine in the cigarette is a chemical substance with strong toxicity, and can stimulate and be absorbed by mucosa, so that adverse reaction occurs in nervous system, adverse effect is caused to blood vessel through nerve, vasospasm and increase of vascular permeability are caused, arterial blood pressure increase, heart rate increase, arrhythmia and the like are promoted; carbon monoxide in cigarette is an important factor causing ischemic cardiovascular disease; cigarette smoke also contains arsenic, toxins produced by mold, ammonia, and other gases. In addition, the smoke particles in the smoke are about 5 ten thousand times more than the particles in the ordinary air, and a large amount of toxin is contained in the smoke particles, so that cilia and mucus of the respiratory tract lose the due protection effect. It can be seen that cigarette smoke is highly irritating to the respiratory tract and causes damage to the mucous membranes.

Along with the popularization of smoking harm knowledge, electronic cigarettes gradually become healthy substitutes for cigarettes. Most of the existing electronic cigarettes use a liquid atomizer, a battery, a heating coil and a liquid storage to produce steam, the liquid is heated in the atomizer and is vaporized at about 65-120 ℃, and a smoker can use the cigarette by pressing a button or making a smoking action.

Common ingredients in the electronic cigarette comprise nicotine, a solvent, a stabilizer, a plasticizer, spice, a preservative and the like, the electronic cigarette still has stimulation to throat even though the harm of the electronic cigarette is reduced compared with that of a traditional cigarette, and phenomena of throat discomfort, excessive phlegm, allergy and the like can occur in part of people.

Medium Chain Triglycerides (MCT) are saturated fatty acids and are used as solvents and carriers for flavorants and pigments in the food and cigarette additive industry, and as specialty foods for post-surgical, infected, and skin burn patients. Currently, medium chain triglycerides have been used in smoking articles, such as e-cigarettes, often as solvents or to improve mouthfeel.

Patent WO2013116558a1 discloses an electronic article for smoking comprising at least one additive dispersed in a fibrous element, said additive comprising MCT for improving the mouth feel.

Patent EP2578093B1 discloses a cigarette filter comprising a flavour in a solvent MCT.

Patent CN105925376A discloses an essence for cigarette blasting beads and application thereof, comprising 2, 3-dimethylpyrazine, clove bud oil, lactic acid, ethyl maltol, ethyl cyclopentenolone, vanillin, 2, 6-dimethoxyphenol and medium chain triglyceride, wherein 15-20 μ L of the essence is wrapped in a capsule in an injection perfuming manner and then is placed in the middle of a filter tip of a cigarette.

Patent CN201710288603.X discloses a medlar essence for cigarette blasting beads and application thereof in cigarettes, wherein the medlar essence comprises medlar extract, isoamyl acetate, phenethyl alcohol, ethyl benzoate, o-bitter orange oil and caprylic capric glyceride, and after the blasting beads prepared by the essence are placed into cigarette filters, the irritation of the cigarettes can be weakened, and the fragrance of the cigarettes can be improved and enriched.

The inventor surprisingly finds that the stimulation of the electronic cigarette liquid to the respiratory tract can be improved and/or reduced by using the medium-chain triglyceride, and particularly, the stimulation of the auxiliary material propylene glycol commonly used in the electronic cigarette liquid to the respiratory tract can be improved and/or reduced by using the medium-chain triglyceride, so that discomfort symptoms such as cough, allergy, excessive phlegm and the like which can occur when the electronic cigarette is used can be relieved.

Disclosure of Invention

It is an object of the present invention to provide the use of medium chain triglycerides for improving and/or reducing the irritation of the respiratory tract.

It is a further object of the present invention to provide the use of medium chain triglycerides for the preparation of a product for improving and/or reducing respiratory tract irritation.

It is a further object of the present invention to provide a composition comprising medium chain triglycerides for use in improving and/or reducing the irritation of the respiratory tract.

Another object of the invention is to provide a use of an e-liquid comprising medium chain triglycerides for improving and/or reducing the irritation of the respiratory tract.

In particular, in a first aspect, the present invention provides the use of medium chain triglycerides to ameliorate and/or reduce respiratory irritation, preferably respiratory irritation caused by the administration of tobacco products, more preferably respiratory irritation caused by the administration of electronic cigarettes.

In a second aspect, the present invention provides the use of a medium chain triglyceride in the manufacture of a product for improving and/or reducing respiratory irritation, preferably respiratory irritation caused by the administration of a tobacco product, more preferably respiratory irritation caused by the administration of an electronic cigarette.

In a specific embodiment of the present invention, the product for improving and/or reducing respiratory tract irritation comprises medium chain triglycerides, preferably the product for improving and/or reducing respiratory tract irritation comprises 1-99% by weight of medium chain triglycerides, more preferably the product for improving and/or reducing respiratory tract irritation comprises 20-90% by weight of medium chain triglycerides, particularly preferably the product for improving and/or reducing respiratory tract irritation comprises 30-90% by weight of medium chain triglycerides, for example, the product for improving and/or reducing respiratory tract irritation comprises 30%, 40%, 50%, 60%, 70%, 80%, 90% by weight of medium chain triglycerides.

In a particular embodiment of the invention, the medium chain triglycerides are either used as an additive in the preparation of a product for ameliorating and/or reducing respiratory irritation, or are removed prior to the preparation of a product for ameliorating and/or reducing respiratory irritation, leaving only residual components in the product.

The respiratory tract stimulation can be stimulation generated by toxic ingredients in the tobacco or stimulation generated by auxiliary materials added in the tobacco. In an embodiment of the present invention, the respiratory tract irritation is irritation caused by an additive such as nicotine, a solvent, a preservative, a stabilizer, and a perfume in the electronic cigarette, and preferably, the respiratory tract irritation is irritation caused by an additive such as propylene glycol in the electronic cigarette.

The solvent is selected from one or the combination of more than two of ethanol, diethylene glycol, triethylene glycol, glycerol, propylene carbonate, propylene glycol, butanediol or polyethylene glycol.

The preservative is selected from one or the combination of more than two of ascorbic acid, chlorphenesin, sodium benzoate, methyl paraben, ethyl paraben, propyl paraben or sodium paraben mixed ester.

The stabilizer is one or the combination of more than two of pectin, konjac glucomannan, xanthan gum, oxidized modified starch, sodium alginate and sodium caseinate.

The spice is selected from one or the combination of more than two of peppermint oil, anethole, essence and lemon oil.

The propylene glycol of the present invention comprises 1, 2-propylene glycol and/or 1, 3-propylene glycol.

The carbon chain of the medium chain triglyceride of the present invention contains 6 to 12 carbon atoms, preferably the carbon chain of the medium chain triglyceride contains 7 to 11 carbon atoms, and more preferably the carbon chain of the medium chain triglyceride contains 8 to 10 carbon atoms.

Preferably, the medium chain triglyceride is selected from one or a combination of two or more of saturated caprylic acid triglyceride, saturated capric acid triglyceride or saturated caprylic-capric acid mixed triglyceride. In one embodiment of the invention, the use of saturated caprylic triglyceride in the preparation of an electronic cigarette liquid for improving and/or reducing respiratory tract irritation is provided.

In another embodiment of the invention, the use of saturated capric triglyceride in the preparation of an e-liquid for ameliorating and/or reducing respiratory irritation is provided.

The improvement and/or reduction of respiratory tract irritation described herein includes improvement and/or reduction of upper respiratory tract irritation, lower respiratory tract irritation, and diseases or symptoms caused by upper and lower respiratory tract irritation.

The upper respiratory tract irritation and diseases caused by the upper respiratory tract irritation described herein include, but are not limited to, pharyngitis, laryngitis, rhinitis, sinusitis, and upper respiratory tract infections.

The lower respiratory tract irritation and diseases caused by the lower respiratory tract irritation described herein include, but are not limited to, cough, trachitis, chronic bronchitis, acute bronchitis, lower respiratory tract infection, expectoration, asthma, airway obstruction, pneumonia, emphysema, tuberculosis, atelectasis, hypertension, lung cancer, pneumothorax.

The symptoms caused by the respiratory tract irritation are selected from one or the combination of more than two of nasal obstruction, watery nasal discharge, sneezing, cough, excessive phlegm, pharyngeal discomfort, pharyngeal congestion, pharyngalgia, fever, dysphoria, headache, general discomfort, hypodynamia, tonsil swelling and large lower jaw and cervical lymph node swelling.

In a particular embodiment of the invention, the symptoms caused by said respiratory irritation are selected from the group consisting of respiratory irritation, including cough, sputum and angina, caused by the administration of propylene glycol in tobacco products.

In a third aspect, the present invention provides a composition comprising medium chain triglycerides and a food or pharmaceutical acceptable adjunct material, wherein the composition is useful for ameliorating and/or reducing respiratory irritation.

In a specific embodiment of the invention, the composition comprises medium chain triglycerides, preferably the composition comprises 1-99% medium chain triglycerides, more preferably the composition comprises 20-90% medium chain triglycerides, especially preferably the composition comprises 30-90% medium chain triglycerides, for example the composition comprises 30%, 40%, 50%, 60%, 70%, 80%, 90% medium chain triglycerides.

Preferably, the carbon chain of the medium chain triglyceride contains from 7 to 11 carbon atoms, more preferably, the carbon chain of the medium chain triglyceride contains from 8 to 10 carbon atoms.

Preferably, the medium chain triglyceride is selected from one or a combination of two or more of saturated caprylic acid triglyceride, saturated capric acid triglyceride or saturated caprylic-capric acid mixed triglyceride.

The food or medicine acceptable auxiliary materials are selected from one or the combination of more than two of carriers, excipients, diluents, lubricants, wetting agents, emulsifiers, preservatives, antioxidants, buffering agents, bacteriostats, suspending agents, solubilizers, thickening agents, stabilizers, sweeteners and spices.

The compositions of the present invention may be in the form of solutions, suspensions, powders, granules, tablets, capsules, lozenges, gels, emulsions and the like.

In a fourth aspect, the invention also provides the use of said composition in the manufacture of a product for improving and/or reducing respiratory irritation. The formulations of the compositions are preferably in unit dosage form, which is subdivided into unit doses containing appropriate amounts of the active ingredient. The unit dosage form may be a packaged preparation and contain discrete quantities of the preparation, such as solutions, tablets, capsules, and powders packaged in vials or ampoules. The composition of the invention can be added to or used in the preparation of tobacco products, for example, the composition can be added to electronic cigarette liquid, or the composition can be used as a solvent for preparing tobacco products. In the context of the present invention, the dosage administered to a subject should be sufficient and produce a beneficial response in the subject over time. The dosage will depend upon the potency of the particular composition employed and the condition of the subject.

The products for improving and/or reducing the respiratory tract irritation comprise but are not limited to cigarette products, food, medicines or health care products, and preferably, the products are cigarette liquid, bead blasting, flavoring agents and the like.

Therefore, in another aspect of the present invention, an e-liquid is provided, where the e-liquid includes 1% to 99% of medium chain triglycerides by mass, preferably, the e-liquid includes 20% to 90% of medium chain triglycerides, and particularly preferably, the e-liquid includes 30% to 90% of medium chain triglycerides, for example, the e-liquid includes 30%, 40%, 50%, 60%, 70%, 80%, 90% of medium chain triglycerides.

In the specific embodiment of the invention, the electronic cigarette liquid further comprises one or more than two of other natural plant extracts, solvents, preservatives, stabilizers or spices.

In a specific embodiment of the invention, the tobacco liquid comprises 0.9-98% of solvent by weight percentage, preferably, the electronic tobacco liquid contains 9-79% of solvent, and particularly preferably, the electronic tobacco liquid contains 9-69% of solvent.

In a specific embodiment of the invention, the tobacco liquid comprises 1-5% by weight of the stabilizer, and preferably, the tobacco liquid comprises 2-4% by weight of the stabilizer.

In a specific embodiment of the present invention, the tobacco liquid comprises 0.1-5% by weight of the perfume, and preferably, the tobacco liquid comprises 0.1-1% by weight of the perfume.

In a specific embodiment of the invention, the tobacco liquid comprises 0.1-3% by weight of preservative, preferably, the tobacco liquid comprises 0.1-1% by weight of preservative.

In a specific embodiment of the invention, the tobacco liquid comprises 0.1-30% by weight of other natural extracts, and preferably, the tobacco liquid comprises 0.1-10% by weight of other natural extracts.

The invention also provides application of the electronic cigarette liquid in improving and/or reducing respiratory tract irritation. Preferably, said improving and/or reducing respiratory irritation is a non-therapeutic objective.

Unless otherwise indicated, the term "food or pharmaceutically acceptable additional adjuvant" means that the ingredient is free of biologically or otherwise undesirable impurities, e.g., the ingredient may be incorporated into the disclosed food or pharmaceutical product and administered to the user without causing significant undesirable biological effects or interacting in a deleterious manner with other ingredients contained in the formulation.

Unless otherwise indicated, the term "ameliorating and/or reducing" includes inhibiting, delaying, moderating, attenuating, limiting, alleviating, or resolving a disease, disorder, or condition.

Unless otherwise specified, the term "comprising" means "open" or "inclusive" such that they include the recited elements, but also allow for the inclusion of additional, unrecited elements.

Detailed Description

The technical solutions of the present invention will be described clearly and completely with reference to the following embodiments of the present invention, and it should be understood that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Example 1 preparation of nicotine-containing electronic cigarette liquid

Prescription:

the preparation method comprises the following steps:

weighing the components according to the formula, dissolving nicotine in MCT, 1, 2-propylene glycol and purified water, adding sodium benzoate after dissolving, finally adding essence, and fully stirring to obtain the electronic cigarette liquid.

Example 2 preparation of nicotine-containing electronic cigarette liquid

Prescription:

the preparation method comprises the following steps:

Example 3 preparation of e-liquid without MCT

Prescription:

the preparation method comprises the following steps:

weighing the components according to the formula, dissolving nicotine in glycerol, 1, 2-propylene glycol and purified water, adding sodium benzoate after dissolving, finally adding essence, and fully stirring to obtain the electronic cigarette liquid.

EXAMPLE 4 Effect of MCT in tobacco juice on user

The first, material and method:

1.1 study population

To study the efficacy of medium chain triglycerides, 50 persons enrolled to smoke the medium chain triglyceride containing electronic cigarette of example 1 were experimental groups and controls were performed according to the age of the experimental group of persons matched to 50 persons smoking the medium chain triglyceride free electronic cigarette of example 3. Two groups of people are strictly controlled to keep the same common mixed diet, living environment and living and sports habits for 3 months. The persons in the experimental group and the control group had no serious respiratory diseases.

1.2 methods of investigation

The influence of medium chain triglycerides on the improvement of propylene glycol-induced respiratory irritation was investigated by taking the control of the individuals in the experimental and control groups. The intervention mode comprises the following steps: (1) the experimental group smoked the electronic cigarette containing saturated caprylic triglyceride prepared in example 1 once a day, and smoked one electronic cigarette each time; (2) the control group smoked the ordinary electronic cigarette prepared in example 3 once a day, one cigarette at a time. The observation course is four weeks, and cough, phlegm and pharyngalgia symptoms of the people after the experiment are observed.

Second, experimental results

The results show that the number of people who have cough, sputum and pharyngalgia symptoms after smoking the electronic cigarette containing MCT prepared in example 1 is obviously less than that after smoking the electronic cigarette without MCT prepared in example 3, and the MCT can improve the respiratory tract irritation caused by propylene glycol in the electronic cigarette liquid.

Example 5 Effect of MCT on spray-induced cough in mice

Firstly, experimental animals:

60 ICR mice (18-22 g) were divided into 6 groups of 10 mice each, each half of which was male and female, at random according to body weight.

Secondly, a spraying scheme:

thirdly, an experimental scheme:

before the test, mice of each group are fasted for 16 hours, the mice are placed in a cough-inducing asthma-inducing instrument, tobacco liquid is prepared according to the tobacco spraying scheme, 6mg of the tobacco liquid is heated, atomized and sprayed into the cough-inducing asthma-inducing instrument for 3 times every day for 5 days, the number of days when the cough appears for the first time and the total number of times of the cough within 5min after each spraying are observed and recorded, wherein the number of times when the cough appears for the first time on the Nth day is recorded as N points (the number of times when the cough still does not appear on the Nth day is recorded as N points), and the average score of the number of days when the cough appears for the first time and the average accumulated total number of times of the cough in each group are calculated.

Fourthly, experimental results:

the results show that the smoke solution can obviously relieve the cough caused by smoking the smoke of the mice when 30-90% of MCT is added into the smoke solution, particularly, the effect of relieving the cough caused by smoking the smoke of the mice is better when 90% of MCT is added into the smoke solution, and the comparison result of the experimental group 1 and the control groups 1 and 2 shows that the MCT in the smoke solution is more effective in relieving the cough caused by 1, 2-propanediol.

The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.

It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.

Claims

1. Use of a medium chain triglyceride selected from one or a combination of two or more of saturated caprylic triglyceride, saturated capric triglyceride or saturated caprylic-capric mixed triglyceride to improve and/or reduce respiratory irritation, wherein the respiratory irritation is irritation caused by propylene glycol in tobacco products when the tobacco products are administered, the respiratory irritation is irritation caused by the administration of electronic cigarettes, the irritation caused by propylene glycol in tobacco products is irritation of the upper respiratory tract, irritation of the lower respiratory tract and diseases or symptoms caused by irritation of the upper and lower respiratory tracts, wherein the propylene glycol comprises 1, 2-propylene glycol and/or 1, 3-propylene glycol, and the carbon chain of the medium chain triglyceride contains 6 to 12 carbon atoms.

2. Use of medium chain triglycerides according to claim 1 for the preparation of a product for improving and/or reducing respiratory tract irritation, wherein the carbon chain of the medium chain triglycerides contains 8-10 carbon atoms.

3. Use of a medium chain triglyceride selected from one or a combination of two or more of saturated caprylic acid triglyceride, saturated capric acid triglyceride or saturated caprylic-capric acid mixed triglyceride in the manufacture of a product for improving and/or reducing respiratory irritation caused by propylene glycol in a tobacco product when the tobacco product is administered.

4. Use of medium chain triglycerides according to claim 3 for the preparation of a product for improving and/or reducing respiratory tract irritation, wherein the product is selected from the group consisting of tobacco products, food products, pharmaceutical products, health products.

5. Use of medium chain triglycerides according to claim 4 for the preparation of a product for improving and/or reducing respiratory tract irritation, wherein the product is selected from the group consisting of a liquid smoke, a popping bead, or a flavoring agent.

6. Use of medium chain triglycerides according to claim 4 for the preparation of a product for improving and/or reducing respiratory tract irritation, wherein the product comprises medium chain triglycerides in an amount of 1-99% by weight.

7. Use of medium chain triglycerides according to claim 4 for the preparation of a product for improving and/or reducing respiratory tract irritation, wherein the product comprises 20-90% medium chain triglycerides by weight.

8. Use of medium chain triglycerides according to claim 4 for the preparation of a product for improving and/or reducing respiratory tract irritation, wherein the product comprises 30-90% medium chain triglycerides by weight.